🇺🇸 THALLOUS CHLORIDE in United States

FDA authorised THALLOUS CHLORIDE on 23 October 1979 · 65 US adverse-event reports

Marketing authorisations

FDA — authorised 23 October 1979

  • Application: NDA018150
  • Marketing authorisation holder: CURIUM
  • Status: supplemented

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dyspnoea — 9 reports (13.85%)
  2. Tremor — 9 reports (13.85%)
  3. Dizziness — 8 reports (12.31%)
  4. Nausea — 8 reports (12.31%)
  5. Chills — 7 reports (10.77%)
  6. Hyperhidrosis — 7 reports (10.77%)
  7. Asthenia — 5 reports (7.69%)
  8. Feeling Abnormal — 4 reports (6.15%)
  9. Hepatitis B — 4 reports (6.15%)
  10. Urticaria — 4 reports (6.15%)

Source database →

THALLOUS CHLORIDE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is THALLOUS CHLORIDE approved in United States?

Yes. FDA authorised it on 23 October 1979; FDA has authorised it.

Who is the marketing authorisation holder for THALLOUS CHLORIDE in United States?

CURIUM holds the US marketing authorisation.